Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the treatment of obesity and type 2 diabetes, and a growing body of observational research suggests a potential association between the use of these medications and reduced risk of breast cancer as well.
During the 2026 San Antonio Breast Cancer Symposium®, a special session, Modern Weight-Loss Drugs and Breast Cancer, will examine these preliminary findings as well as the many unanswered questions about the relationship between modern weight-loss strategies, including the GLP-1 receptor agonists semaglutide and tirzepatide, and breast cancer risk and outcomes. The session will be held Tuesday, December 8, from 12:45 to 2:15 p.m. CT in Hemisfair Ballroom 1-2 at the Henry B. Gonzalez Convention Center.

“This session will explore the biological changes that occur as a result of modern weight-loss therapies. Presentations during the session will also review what we know—and what we don’t know—about the impact of GLP-1s on breast cancer risk and outcomes,” said session moderator Jennifer A. Ligibel, MD, of the Dana-Farber Cancer Institute.
Stephen D. Hursting, PhD, MPH, of the University of North Carolina Lineberger Comprehensive Cancer Center, will offer information on the broader physiologic impacts of modern obesity therapies, including GLP-1 receptor agonists, on metabolism and immunity.
“This first presentation will provide a mechanistic perspective on the effect of GLP-1s and other weight-loss strategies on metabolic, transcriptional, and immunologic outcomes,” Dr. Ligibel said.
Saba Shaikh, MD, of UT Health San Antonio, will discuss the potential of weight-loss agents for the prevention of breast cancer.
Joshua Gruber, MD, PhD, of Stanford University, will close out the session with a presentation on the biological and clinical impact of GLP-1 receptor agonists in patients who are treated with immune checkpoint inhibitors.
Vernal Branch, who serves on the SABCS Program Planning Committee, will also share her perspective as a breast cancer survivor and independent research patient advocate.
“We will highlight the many unanswered questions regarding the role of GLP-1s in breast cancer prevention and control,” Dr. Ligibel said, “hopefully inspiring research to help us understand how these promising agents should be used to reduce the burden of breast cancer in our patients.”
Session titles, times, and locations are subject to change. For the most up-to-date SABCS 2026 program information, please visit the Program page at SABCS.org.


